Excellamol’s clinical programs are currently in development to provide injectable long-acting OncoPDCs for the treatment of hard-to-reach cancers; High-grade glioma, pediatric diffuse midline glioma (DMG), and pancreatic ductal adenocarcinoma (PDAC). Two INTERACT meetings have been scheduled with the US FDA to obtain feedback on the safety pharmacology and toxicokinetics of XM161-SN38 and XM182-Exatecan prior to initiating clinical trials in glioblastoma.